News

Fewer hospitalizations seen in HAE patients using Orladeyo: US study

Treatment with oral Orladeyo (berotralstat) led to significantly fewer disease-related or all-cause hospitalizations and emergency room visits by people with hereditary angioedema (HAE) in the U.S., according to a real-world claims analysis. “The data presented here represent the first documentation that prescribing Orladeyo significantly reduces healthcare resource utilization,”…

HAE International asks supporters to ‘step’ up for HAE Awareness Day

Hereditary Angioedema (HAE) Awareness Day is observed every May 16 to call attention to a disorder that affects an estimated 1 in 50,000 to 150,000 people globally. Called “hae day :),” the observance targets targets policymakers, industry representatives, public authorities, researchers, and healthcare professionals, along with the general public.

Orladeyo approved in Brazil for HAE patients 12 and older

The once-daily oral therapy Orladeyo (berotralstat) has been approved in Brazil to prevent swelling attacks in people, 12 and older, with hereditary angioedema (HAE). The approval by the Brazilian Health Regulatory Agency (ANVISA) makes Orladeyo the first oral prophylactic (preventive) therapy authorized for HAE patients in the country.